Printer Friendly

Development of a LC-MS/MS Method for the Simultaneous Detection of Tricarboxylic Acid Cycle Intermediates in a Range of Biological Matrices.

1. Introduction

The tricarboxylic acid (TCA) cycle, also known as Krebs' cycle, represents a crucial metabolic pathway in almost all living organisms [1]. It encompasses a cyclic series of reactions that oxidises citrate to generate NADH (reduced form of nicotinamide adenine dinucleotide, NAD) and a series of metabolites that can be used for amino acid and lipid synthesis, as well as the regeneration of citrate through the condensation of acetyl CoA with oxaloacetate (Figure 1) [2]. NADH feeds into oxidative phosphorylation to generate adenosine-triphosphate (ATP) [3]. In certain cell types and pathological conditions citrate is exported from mitochondria as opposed to being oxidised [4,5]. For example, healthy prostate epithelial cells have a modified TCA cycle that favours the export of citrate out of the mitochondrion to provide an energy source for spermatozoa [6]. Likewise, many cancer cells favour the export of citrate for lipid synthesis [7]. The different metabolic fate of citrate between healthy and cancer cells has been the focus of attention of several research groups, and has been studied as possible adjunct to diagnosis and a target for cancer therapy [8-12]. Many of published reports on the analyses of intermediates of the TCA cycle, including citrate, have used enzymatic or Nuclear Magnetic Resonance (NMR) methods for their detection and quantification [5,13-15]. Studies that used enzymatic methods often relied on spectrophotometric methods and thus provide indirect measurement of citrate and related TCA cycle intermediates [16-18]. NMR offers the advantage of requiring minimal sample preparation but lacks the sensitivity in comparison to liquid chromatography (LC) [19]. Analysis of small molecules using targeted liquid chromatography tandem mass spectrometry (LC-MS/MS) is thought to provide higher sensitivity especially from matrices where compounds or molecules are at low concentrations [20,21]. Our aim was to develop a LC-MS/MS method that would allow the simultaneous detection of TCA cycle intermediates in different biological matrices of human origin with a relatively easy sample preparation and high sensitivity. Previous studies have described the application of liquid chromatographic methods coupled with mass spectrometry for the determination of specific intermediates of the Krebs cycle (e.g., succinic acid, citric acid) in body fluids [22,23]. The simultaneous determination of TCA intermediates has been described in natural waters or bacterial cultures [24-26], but there are only few reports in samples of human origin including tumour specimens [27-29]. This study reports the development and validation of an extraction method from human plasma, urine, prostate tissue, and cultured cells that allows the qualitative and quantitative analysis of TCA cycle intermediates by using LC-MS/MS. It was envisaged that the simultaneous detection and quantification of these key metabolites by LC-MS/MS could be a useful research tool and may provide a more holistic picture of the changes that occur in the TCA cycle in different cancer types including prostate cancer.

2. Experimental

2.1. Chemicals and Reagents. Tricarboxylic acid standards [glutamic acid ([greater than or equal to] 99%), citric acid ([greater than or equal to] 99%), isocitric acid ([greater than or equal to] 93%), [alpha]-ketoglutaric acid ([greater than or equal to] 99%), malic acid ([greater than or equal to] 99%), oxaloacetic acid ([greater than or equal to] 97%), succinic acid ([greater than or equal to] 9%), and fumaric acid ([greater than or equal to] 99%)] were purchased from Sigma[R] (Sigma-Aldrich Company Ltd., Dorset, UK). Lactic acid ([greater than or equal to] 85%) was also obtained from Sigma (Sigma-Aldrich Company Ltd., Dorset, UK). Deuterated D4-citric acid (2,2,4,4-D4, 98%) was purchased from Cambridge Isotope Laboratories, Inc. (CK Isotopes Ltd., Leicestershire, UK). Synthetic urine control sample and fatty acid-free human serum albumin (HSA) were purchased from Sigma (Sigma-Aldrich Company Ltd., Dorset, UK). Trichloroacetic acid and perchloric acid were purchased from Sigma (Sigma-Aldrich Company Ltd., Dorset, UK). Water was obtained from a Milli-Q[R] Integral Water Purification System (Millipore Limited, Hertfordshire, UK).

2.2. Human Body Fluids. For purposes of method development and with local ethical approval, urine (n = 5) and plasma (n = 10) samples were obtained from healthy subjects. Plasma samples (10 [micro]l) were mixed with 5% trichloroacetic acid (80 [micro]l) and 0.1 mg/ml internal standard (deuterated D4citric acid, 10 [micro]l). The mixture was vortexed for 30 seconds and kept on ice for 5 minutes (vortex twice/2 minutes). Samples were centrifuged at 17,000 xg for 10 minutes (4[degrees]C) and supernatants were transferred to HPLC vials for analysis by LC-MS/MS. After filtration by using a minisart Sterile-ED 0.20 [micro]m filter, urine samples (10 [micro]l) were added to 0.2% formic acid (80 [micro]l) and 0.1 mg/ml internal standard (deuterated D4-citric acid, 10 [micro]l). The mixture was vortexed for 30 seconds and kept on ice for 5 minutes (vortex twice/2 minutes). Samples were then centrifuged at 13,000 xg for 5 minutes (4[degrees]C). Supernatants were transferred to HPLC vials and analysed by the LC-MS/MS on the same day.

2.3. Human Prostate Tissue. Frozen samples of histologically proven benign (n = 5) and cancer (n = 5) prostate tissue were obtained from the Norwich Biorepository (Norfolk and Norwich University Hospital Human Tissue Bank). Benign tissue samples were obtained from patients undergoing radical prostatectomy for organ confined prostate cancer. The protocol was approved by the Faculty of Medicine and Health Science Research Ethics Committee in January 2013 (Reference: 2012/2013-37). Tissue samples were kept at -80[degrees]C until pulverized with liquid nitrogen using a tissue grinder (BioPulverizer, Stratech Scientific Limited, Newmarket, UK). 500 [micro]l of 3 M perchloric acid was added to each 20 mg of tissue powder and homogenised using an automated tissue homogeniser (IKA Ultra-Turrax T8 Disperser, Fisher Scientific Ltd, Loughborough, UK) for 1 minute on medium speed. The homogenate was left on ice for 10 minutes and then centrifuged at 12,000 xg for 10 minutes at 2-4[degrees]C. Supernatants were transferred to HPLC vials and analysed by the LC-MS/MS on the same day.

2.4. Human Cell Lines. Human cancerous prostate adenocarcinoma (PC3) cells were purchased from European Collection of Authenticated Cell Cultures (ECACC) (number 90112714). Cells were routinely cultured as monolayers in Ham's F-12 medium supplemented with 10% foetal bovine serum (FBS) in a humidified atmosphere containing 5% C[O.sub.2] at 37[degrees]C. The culture medium was changed every two days. Cells were grown to 80% confluency on 10 cm dishes before performing the extraction of the TCA cycle intermediates. Briefly, cells were washed twice with 10 ml 0.9% sodium chloride (Sigma-Aldrich Company Ltd., Dorset, UK) and were harvested using 0.025% (w/v) trypsin (Gibco[R], Fisher Scientific Ltd, Loughborough, UK) in a phosphate-buffered saline solution (D-PBS w/o Calcium Magnesium) (Fisher Scientific Ltd, Loughborough, UK). After cell count with a haemocytometer, cell suspensions were centrifuged at 1,200 xg for 10 minutes at room temperature. After discarding the supernatant, cells were gently suspended by adding 10 ml of 0.9% sodium chloride before centrifugation at 1,200 xg for 10 minutes. The supernatant was then removed and 0.5 ml of perchloric acid (0.3 mM) was added. The mixture was kept on ice for 10 minutes followed by further centrifugation at higher speed of 12,000 xg for 10 minutes. Supernatant was then transferred to HPLC vials and kept at -20[degrees]C until required for analysis. LC-MS/MS analysis was carried out within 24-72 hours from sample collection. All reagents were kept on ice (below 6[degrees]C) at all times. The concentration of all TCA analytes was normalised per [10.sup.6] cells. TCA cycle intermediates were also extracted in culture media. Briefly, the culture medium was collected before harvesting PC3 cells with trypsin and 10% of perchloric acid (3 mM) was added. Samples were kept on ice for 10 minutes followed by further centrifugation (12,000 xg for 10 minutes) as described for cell pellets.

2.5. LC-MS/MS Analysis. TCA standards were reconstituted in mobile phase (0.2% formic acid) to prepare 1mg/ml stock solutions. All stock solutions were prepared daily just before running samples in the LC-MS/MS system. A standard curve of each analyte (glutamic acid, citric acid, isocitric acid, [alpha]-ketoglutaric acid, malic acid, oxaloacetic acid, succinic acid, fumaric acid, and lactic acid) was produced from stock solutions (1mg/ml) in the relevant matrix (synthetic urine, 5% fatty acid-free HSA, cell culture medium acidified with 0.2% formic acid). 100 [micro]l of each standard was mixed in a total volume of 1 ml to obtain a mixed standard solution (100 [micro]g/ml each standard). A five-point standard curve was produced with a 10-fold serial dilution from the highest concentration to 0. 10 [micro]l of deuterated D4-citric acid was added to all samples as an internal standard (final concentration of 10 [micro]g/ml) to allow quantification based on the ratio of the internal standard to each intermediate peak. Agilent 1200 series LC 6490 Triple Quad LC-MS mass spectrometer was used (Agilent Technologies, CA, US). Phenomenex[R] Luna C18, Kinetex PFP, Kinetex XB-C18, and Kinetex-C18 columns were used to achieve an optimal separation of all TCA intermediates and to obtain good peak shapes. The flow rate was 0.4ml/minute with a mobile phase of 0.2% formic acid. Electrospray ionisation (ESI) was used in the positive mode (ES[I.sup.+]) for glutamic acid and in the negative mode (ES[I.sup.-]) for the other TCA cycle intermediates. 2 [micro]l was used for the injection volume and the autosampler was maintained at 4[degrees]C. The Agilent 6490 Triple Quad LC-MS/MS system comprised a degasser, binary pump, cooled autosampler, column oven, and 6490 mass spectrometer. The gas temperature was 200[degrees]C and flow was 16 l/minute; sheath gas temperature was 300[degrees]C with flow of 11 l/minute and nebuliser pressure of 50 psi. Capillary voltage was 3500[degrees]C and 3000[degrees]C for positive and negative polarity, respectively. The LC eluent flow was sprayed into the mass spectrometer interface without splitting. TCA cycle intermediates were monitored by tandem MS using multiple reaction monitoring (MRM) mode. Identification was achieved based on retention time and product ions. Table 1 summarises the monitored ions and the optimised MS operating parameters of the analytes.

2.6. Analytical Validation

2.6.1. Linearity. Calibration curves were obtained by using authentic standards (glutamic acid, citric acid, isocitric acid, malic acid, succinic acid, fumaric acid, and lactic acid) spiked in a matrix containing deuterated D4-citric acid as internal standard. Ratio of analyte and internal standard peak area was plotted against the corresponding concentration to obtain the calibration curve.

2.6.2. Sensitivity. LOD and LOQ were calculated by injection of diluted solutions of TCA intermediates in each matrix. LOD was estimated as the concentration of TCA intermediates that generated a peak with an area at least 3 times higher than the baseline noise. LOQ was calculated at a signal to-noise ratio 10 times higher than the baseline noise of these compounds.

2.6.3. Precision and Accuracy. To assess within run precision, plasma samples (n = 10) were analysed and the precision of retention time and concentration was assessed. The bioanalytical precision and accuracy of this method were calculated by analysing the same samples on 5 days for interday precision.

2.6.4. Carry-Over Effect. Agilent 1200 series high performance autosampler with an injection program was used to minimise carry-over effects. Carry-over was assessed by injecting acidified water after an injection of the highest concentration of the TCA standards.

2.6.5. Extraction Recovery and Matrix Effect. The matrix effect was assessed by using the postextraction spike method as indicated by RSC guideline for LC-MS measurements [30]. The same concentration of TCA intermediates was spiked in two matrices: (1) 0.2% formic acid in water to assess the LC-MS/MS method and (2) acidified synthetic urine (urine analysis) or 5% fatty acid-free HAS (plasma analysis) to assess the matrix effect with deuterated D4-citric acid as internal standard.

2.7. Data Analysis. Data files were explored and analysed using MassHunter Quantitative B.06 Workstation software (Agilent Technologies, CA, US). The peak area of each analyte was determined, and the concentration of the analyte was calculated using the peak area ratio (peak area of analyte/peak area of the internal standard).

3. Results

3.1. Optimisation of Mass Spectroscopy Conditions. The automated Agilent MassHunter Optimiser software was used to obtain precursor and products ions in each analyte. The collision energy was used from 0 to 80 by 10 CE step increment in negative polarity mode for all analytes except for glutamic acid in positive polarity. The fragmentor value was constant, 380 V. Decarboxylation and/or water elimination are the most intense fragmentation patterns for most of the organic acids [25]. The precursor and product ions produced by the Agilent 6490 mass spectrometer were comparable with these patterns. However, in the current study we observed selective fragments which can be useful if further identification is needed. For example, both citric and isocitric acids show a main product ion with m/z 111 corresponding to [[M-H-C[O.sub.2]-2 [H.sub.2]O].sup.-]; however, isocitric acid also gives rise to a relatively stable product ion with m/z 155 corresponding to the neutral loss of two water molecules. The fragment m/z 155 produced by isocitric acid is hardly seen in the fragmentation pattern of citric acid. The same fragment 155 from isocitric acid was also observed by Bylund and colleagues [24]. The fragmentations results are summarised in Table 1.

3.2. Optimisation of LC Parameters. Waters Acquity UPLC HSS C18 and BEH Amide columns were used to achieve an optimal separation of all TCA products by using different mobile phases at different pH values. Most of the TCA cycle intermediates have shown tailing peaks. We found that the use of a Kinetex-C181.7 [micro]m (100 x 2.1 mm) column and guard column from Phenomenex allows good separation and peak shapes using isocratic mobile phase 0.2% formic acid in water.

3.3. Method Validation. The method was validated against published acceptance criteria for linearity, accuracy, precision, recovery, and sample stability [30]. We performed method validation procedures in plasma samples by choosing a matrix that would minimise the interference of endogenous compounds [31]. Due to the high levels of TCA analytes, mainly citric acid, endogenously present in human plasma, 5% fatty acid-free HAS was used for matrix match calibration with the addition of deuterated D4-citric acid as internal standard. Validation was not performed for [alpha]-ketoglutaric and oxaloacetic acids due to their instability.

3.3.1. Linearity and Sensitivity. Calibration curves were linear over a wide range of concentrations, and the least- squares regression calibration curve was [r.sup.2] = 0.999 (Table 2). LOD and LOQ values are also shown in Table 2.

3.3.2. Precision and Accuracy. Intraday precision was evaluated by replicate (n = 10) analysis of a single human plasma sample. The precision was calculated from the relative standard deviation. The CV (%) was less than 10% for all analytes. Interday precision was evaluated by analysing the same sample by the same extraction and LC-MS/MS methods (n = 5 days). The CV (%) was <15% for most of the analytes except for succinic acid (18.9%). The higher CV (%) value for succinic acid can be explained by low plasma concentration of this TCA intermediate. Precision and accuracy data are presented in Table 2.

3.3.3. Carry-Over Effect. One of the most commonly encountered problems in the quantification of metabolites in biological samples by LC-MS/MS technique is carry-over of tested compounds. Several parts of an injection system can contribute to carry-over effect such as needle outside, needle inside, needle seat, sample loop, seat capillary, and injection valve. In our study, we used Agilent 1200 series high performance autosampler with an injection program to minimise carry-over effects. Response for all TCA analytes was approximately zero. Only glutamic acid showed carryover effect (<1%).

3.3.4. Extraction Recovery and Matrix Effect. The recovery of the proposed method was assessed by spiking known amounts of TCA intermediates in two matrices. The matrix effect/ion suppression of all TCA intermediates was <5%, and recoveries were >95%.

3.3.5. Stability. Stocksolutions of TCA standards were freshly prepared before each LC-MS/MS run. However, analysis was repeated with stock solutions kept at -20[degrees]C for 7 days, and no changes were observed. This is in accordance with a study carried out by Keevil and colleagues reporting that citric acid was stable at -20[degrees]C for 30 days [23]. The stability of extracted samples was assessed following 90 injections of the same sample at 4[degrees]C. The CV (%) value was <10% for all the biological matrices tested in this study.

3.4. Analysis of TCA Cycle Intermediates in Human Plasma Samples. Fatty acid-free HSA was used for matrix match calibration with the addition of deuterated D4-citric acid standard as internal standard to enable the simultaneous identification and quantification of TCA cycle intermediates in human plasma (n = 10). The calibration curve of each compound was linear, and the correlation coefficient ranged from 0.9996 to 1.0 in the range of concentrations listed in Table 2. Figure 2 shows the detection of TCA analytes in human plasma. The calibration curve of citric acid was linear in the range of concentrations of 0-520 [micro]M. The average concentrations obtained from plasma samples (143 [+ or -] 39.1 nM) were comparable to known reference ranges of human circulating citrate (100-300 nM) [32,33]. Previous studies confirmed that citrate with an average concentration of 135 [micro]M represents the most abundant intermediate of the TCA cycle in human blood [34].

3.5. Application of This Method to Other Biological Matrices of Human Origin

3.5.1. Analysis of TCA Cycle Intermediates in Human Urine Samples. A synthetic urine sample was used for matrix match calibration with the addition of deuterated D4-citric acid internal standard to enable quantification. Following 10-fold dilution with 0.2% formic acid, TCA cycle intermediates were successfully detected in human urine samples (n = 5). The calibration curve of each compound was linear, and the correlation coefficient ranged from 0.9998 to 0.9999 in the linear range of concentrations of 0-520 [micro]M. An example of detected TCA analytes in human urine is shown in Figure 3. The average level of citric acid in urine was 369.3 [+ or -] 37.1 [micro]g/ml. Previous reports have indicated that urinary citrate excretion ranged between 350 and 1,200 mg/day in healthy subjects [35,36]. Data obtained were comparable to the reported range of urinary citrate excretion in humans taking into account the fact that the normal range for 24-hour urine volume is 800 to 2,000 ml per day.

3.5.2. Analysis of TCA Cycle Intermediates in Human Prostate Tissue. Histologically proven cancerous and benign prostate tissue samples were obtained from the Norwich Biorepository (NNUH) in accordance with local regulatory approvals. Tissue originated from either radical prostatectomy/cystoprostatectomy specimens or transurethral resection of the prostate (TURP). Citrate was successfully detected and quantified by LC-MS/MS in both benign (n = 5) and cancer (n = 5) tissue (Figure 4). The concentration of citrate found in this study was comparable with that of published data [12].

3.5.3. Analysis of TCA Cycle Intermediates in Human Cultured Cell Lines. For the purpose of method development PC3, malignant androgen-independent prostate cells were cultured as previously described. Most of the TCA cycle intermediates were successfully detected and quantified using standard solutions. The calibration curve of each compound was linear and the correlation coefficient ranged from 0.96 to 1.0 in the same linear range of concentrations used for human plasma. Some of the TCA intermediates were more pH sensitive and very unstable such as oxaloacetic and [alpha]-ketoglutaric acids; both of these organic acids were difficult to detect and quantify. LC- MS/MS chromatograms for TCA intermediates detected from PC3 cell lysates are presented in Figure 5. Furthermore, TCA intermediates including citric, isocitric, malic, and succinic acids were successfully detected in culture media of PC3 cells (data not shown).

4. Discussion

The metabolite profiling of tissue and body fluids has become increasingly important to study fundamental aspects of human health and disease, as well as understanding the influence of different factors, such as drugs, diet, and lifestyle changes [37]. The use of LC-MS/MS methods for the quantification of metabolites from biological matrices enables accurate detection of target compounds in relatively low concentrations, reducing interference [20,38].

When examining the TCA cycle intermediates, LC-MS/MS is arguably superior to enzymatic assays that invariably rely on fluorescence techniques to measure concentrations of substrates indirectly and often only allow measurement of one compound at a time [39]. The LC-MS/MS method described in this study allows simultaneous measurement of the majority of TCA cycle intermediates with relatively easy sample preparation. In addition, it allows measurement of lactic and glutamic acids which provide key information regarding the processes of glycolysis and glutaminolysis, both of which influence the concentration of metabolites that are used as substrates in the TCA cycle reactions. In a previous report describing LC-MS/MS quantification of TCA cycle intermediates from soil samples, Bylund and colleagues outlined the retention times and ion mass/charge ratio (m/z) for each of these intermediates [24]. Authors used ion exclusion divinylbenzene column with API3000 mass spectroscopy and the run time of this method was 30 minutes. We achieved a good separation by using a Kinetex C18 reversed-phase column with Agilent 6490 mass spectroscopy in a more time effective manner (run time = 3 minutes). Thus, the proposed method is very fast without compromising the performance of chromatographic separation. The fragmentation patterns were similar to the previous study carried out by Bylund et al. [24]. These fragmentations patterns were used to optimise the method for a wide range of biological matrices (human plasma, urine, prostate tissue, and cell lines). The extraction technique and mobile phase were modified to successfully measure more TCA intermediates in a single run. Our method has significantly improved detection and run time resulting in high sensitivity and relatively short run times. In addition, the two isomers citric and isocitric acids were successfully separated. The achieved separation is very important for quantification purposes, because both acids have the same transitions. We also observed another fragmentation pattern by analysing malic acid, which gave a main product ion 115 and 71. However, the same transition 115/71 was also produced by fumaric acid. Therefore, selective retention times are crucial for the analysis of these two TCA intermediates which were successfully separated by applying our method. However, there are some limitations in measuring [alpha]-ketoglutaric and oxaloacetic acids which were difficult to detect, in particular, in cultured cells. This is likely due to their instability and pH sensitivity, which has been previously reported [25, 40]. However, [alpha]-ketoglutaratic acid was successfully detected in some plasma samples, but it was not quantified due to the instability of the synthetic standard. Further work will be required to develop a method based on carbon-labelled standards for detecting [alpha]-ketoglutaric and oxaloacetic acids as already described by Rabinowitz in Escherichia coli and primary human fibroblast cultures [41].

To summarise, we report a LC-MS/MS method by which it is possible to successfully detect TCA cycle intermediates from a variety of biological sources. Preliminary data confirmed that this method could be also applied for the measurement of TCA intermediates in other human prostate cell lines including human normal prostatic epithelial cells (data not shown). No matrix effect was observed in different matrices due to the sample dilution and low injection volume. Measurement of citric acid, in particular, is shown to be reproducible and comparable to the ranges already reported in published literature [12]. In the last few decades, citrate has been the most studied of these intermediates in relation to prostate metabolism and has often been used as a surrogate for the function of the TCA cycle [34]. It has also been reported that citrate plasma levels are the highest among TCA cycle intermediates in humans [34], and for this reason citrate metabolism is often studied to better understand the role of the TCA cycle in the development of human metabolic diseases [33,42]. The application of this LC-MS/MS method, which has been successfully developed for analysing human samples of different sources in a fast and reliable way, could represent a valuable analytical tool for future research.

5. Conclusions

Measuring TCA cycle intermediates using LC-MS/MS is feasible and allows simultaneous detection and accurate quantification of multiple compounds in different biological matrices. In this paper, we report a fully validated method which offers several advantages in particular in terms of easy sample preparation without derivatization steps, high sensitivity, and short run times. The potential application of this method for analysing the TCA cycle in a wide range of biological matrices could be important in in vitro, ex vivo, and in vivo studies.

Conflicts of Interest

The authors have no conflicts of interest related to this work.


The authors would like to acknowledge the Norwich Biorepository (Norfolk and Norwich University Hospital, Norwich, UK) for providing access to banked tissue samples in compliance with regulatory policies. This work was supported by UK Biotechnology and Biological Sciences Research Council [BB/J004545/1] and the Prostate Cancer Foundation [Challenge Award, 2012].


[1] T. M. Devlin, "The tricarboxylic acid cycle," in Textbook of Biochemistry with Clinical Correlations, pp. 231-266, Wiley-Liss, Inc, Hoboken, NJ, USA, 4th edition, 1997.

[2] O. E. Owen, S. C. Kalhan, and R. W. Hanson, "The key role of anaplerosis and cataplerosis for citric acid cycle function," The Journal of Biological Chemistry, vol. 277, no. 34, pp. 30409-30412, 2002.

[3] P. Mitchell, "Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism," Nature, vol. 191, no. 4784, pp. 144-148, 1961.

[4] J. P. Kavanagh, "Isocitric and citric acid in human prostatic and seminal fluid: implications for prostatic metabolism and secretion," Prostate, vol. 24, no. 3, pp. 139-142, 1994.

[5] E. B. Cornel, G. A. H. J. Smits, J. E. De Ruijter et al., "In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines," The Prostate, vol. 26, no. 5, pp. 275-280, 1995.

[6] L. Costello, "Intermediary metabolism of normal and malignant prostate: a neglected area of prostate research.," The Prostate, vol. 34, no. 4, pp. 303-304, 1998.

[7] M. G. V. Heiden, L. C. Cantley, and C. B. Thompson, "Understanding the warburg effect: the metabolic requirements of cell proliferation," Science, vol. 324, no. 5930, pp. 1029-1033, 2009.

[8] J. E. McDunn, Z. Li, K.-P. Adam et al., "Metabolomic signatures of aggressive prostate cancer," Prostate, vol. 73, no. 14, pp. 1547-1560, 2013.

[9] F. R. O. Silva, C. T. Nabeshima, M. H. Bellini, and L. C. Courrola, "Early diagnosis of prostate cancer by citrate determination in urine with europium-oxytetracycline complex," Applied Spectroscopy, vol. 66, no. 8, pp. 958-961, 2012.

[10] L. C. Costello, R. B. Franklin, and P. Narayan, "Citrate in the diagnosis of prostate cancer," Prostate, vol. 38, no. 3, pp. 237-245, 1999.

[11] E. E. Kline, E. G. Treat, T. A. Averna, M. S. Davis, A. Y. Smith, and L. O. Sillerud, "Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection," Journal of Urology, vol. 176, no. 5, pp. 2274-2279, 2006.

[12] J. Kurhanewicz, D. B. Vigneron, S. J. Nelson et al., "Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy," Urology, vol. 45, no. 3, pp. 459-466, 1995.

[13] M. Petrarulo, P. Facchini, E. Cerelli, M. Marangella, and F. Linari, "Citrate in urine determined with a new citrate lyase method," Clinical Chemistry, vol. 41, no. 10, pp. 1518-1521, 1995.

[14] M. E. Mycielska and M. B. A. Djamgoz, "Citrate transport in the human prostate epithelial PNT2-C2 cell line: electrophysiological analyses," Journal of Physiology, vol. 559, no. 3, pp. 821-833, 2004.

[15] K. Stenman, P. Stattin, H. Stenlund, K. Riklund, G. Grobner, and A. Bergh, "1H HRMAS NMR derived bio-markers related to tumor grade, tumor cell fraction, and cell proliferation in prostate tissue samples," Biomarker Insights, vol. 6, pp. 39-47, 2011.

[16] B. K. Matheson, J. L. Adams, J. Zou, R. Patel, and R. B. Franklin, "Effect of metabolic inhibitors on ATP and citrate content in PC3 prostate cancer cells," Prostate, vol. 67, no. 11, pp. 1211-1218, 2007.

[17] M. E. Mycielska, T. P. Broke-Smith, C. P. Palmer et al., "Citrate enhances in vitro metastatic behaviours of PC-3M human prostate cancer cells: status of endogenous citrate and dependence on aconitase and fatty acid synthase," International Journal of Biochemistry and Cell Biology, vol. 38, no. 10, pp. 1766-1777, 2006.

[18] R. Pal, D. Parker, and L. C. Costello, "A europium luminescence assay of lactate and citrate in biological fluids," Organic and Biomolecular Chemistry, vol. 7, no. 8, pp. 1525-1528, 2009.

[19] D. S. Wishart, "Quantitative metabolomics using NMR," TrAC Trends in Analytical Chemistry, vol. 27, no. 3, pp. 228-237, 2008.

[20] E. Uggerud, S. Petrie, D. K. Bohme et al., "Modern mass spectroscopy," in Topics in Current Chemistry, pp. 1-302, Spriner, Berlin, Germany, 2003.

[21] K. Dettmer, P. A. Aronov, and B. D. Hammock, "Mass spectrometry-based metabolomics," Mass Spectrometry Reviews, vol. 26, no. 1, pp. 51-78, 2007.

[22] C. Hempen, H. Wanschers, and G. Van Der Sluijs Veer, "A fast liquid chromatographic tandem mass spectrometric method for the simultaneous determination of total homocysteine and methylmalonic acid," Analytical and Bioanalytical Chemistry, vol. 391, no. 1, pp. 263-270, 2008.

[23] B. G. Keevil, L. Owen, S. Thornton, and J. Kavanagh, "Measurement of citrate in urine using liquid chromatography tandem mass spectrometry: comparison with an enzymatic method," Annals of Clinical Biochemistry, vol. 42, no. 5, pp. 357-363, 2005.

[24] D. Bylund, S. H. Norstrom, S. A. Essen, and U. S. Lundstrom, "Analysis of low molecular mass organic acids in natural waters by ion exclusion chromatography tandem mass spectrometry," Journal of Chromatography A, vol. 1176, no. 1-2, pp. 89-93, 2007.

[25] B. Luo, K. Groenke, R. Takors, C. Wandrey, and M. Oldiges, "Simultaneous determination of multiple intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by liquid chromatography-mass spectrometry," Journal of Chromatography A, vol. 1147, no. 2, pp. 153-164, 2007.

[26] S. U. Bajad, W. Lu, E. H. Kimball, J. Yuan, C. Peterson, and J. D. Rabinowitz, "Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatographytandem mass spectrometry," Journal of Chromatography A, vol. 1125, no. 1, pp. 76-88, 2006.

[27] H. Hur, M. J. Paik, Y. Xuan et al., "Quantitative measurement oforganic acids in tissues from gastric cancer patients indicates increased glucose metabolism in gastric cancer," PLoS ONE, vol. 9, no. 6, Article ID e98581, 2014.

[28] T. A. Juratli, M. Peitzsch, K. Geiger, G. Schackert, G. Eisenhofer, and D. Krex, "Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas," Neuro-Oncology, vol. 15, no. 6, pp. 682-690, 2013.

[29] S. Richter, M. Peitzsch, E. Rapizzi et al., "Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency," Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 10, pp. 3903-3911, 2014.

[30] M. Sargent, Guide to Achieving Reliable Quantitative LC-MS Measurements, RSC Analytical Methids Committee, 1st edition, 2013.

[31] N. C. van de Merbel, "Quantitative determination of endogenous compounds in biological samples using chromatographic techniques," Trends in Analytical Chemistry, vol. 27, no. 10, pp. 924-933, 2008.

[32] B. Hoppe, M. J. Kemper, M. G. Hvizd, D. E. Sailer, and C. B. Langman, "Simultaneous determination of oxalate, citrate and sulfate in children's plasma with ion chromatography," Kidney International, vol. 53, no. 5, pp. 1348-1352, 1998.

[33] F. Mariano, M. Morselli, D. Bergamo et al., "Blood and ultra-filtrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients," Nephrology Dialysis Transplantation, vol. 26, no. 12, pp. 3882-3888, 2011.

[34] M. E. Mycielska, A. Patel, N. Rizaner et al., "Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer," BioEssays, vol. 31, no. 1, pp. 10-20, 2009.

[35] M. A. Arrabal-Polo, M. Arrabal-Martin, S. Arias-Santiago, J. Garrido-Gomez, A. Poyatos-Andujar, and A. Zuluaga-Gomez, "Importance of citrate and the calcium: citrate ratio in patients with calcium renal lithiasis and severe lithogenesis," BJU International, vol. 111, no. 4, pp. 622-627, 2013.

[36] A. Akdeniz, M. G. Caglayan, and P. Anzenbacher, "A tri-serine tri-lactone scaffold for the quantification of citrate in urine," Chemical Communications, vol. 52, no. 9, pp. 1827-1830, 2016.

[37] K. Bingol, L. Bruschweiler-Li, D. Li, B. Zhang, M. Xie, and R. Bruschweiler, "Emerging new strategies for successful metabolite identification in metabolomics," Bioanalysis, vol. 8, no. 6, pp. 557-573, 2016.

[38] S. Becker, L. Kortz, C. Helmschrodt, J. Thiery, and U. Ceglarek, "LC-MS-based metabolomics in the clinical laboratory," Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 883-884, pp. 68-75, 2012.

[39] S. K. Grebe and R. J. Singh, "LC-MS/MS in the clinical laboratory-where to from here?" Clinical Biochemist Reviews, vol. 32, pp. 5-31, 2011.

[40] S. Lu, X. Sun, C. Shi, and Y. Zhang, "Determination of tricarboxylic acid cycle acids and other related substances in cultured mammalian cells by gradient ion-exchange chromatography with suppressed conductivity detection," Journal of Chromatography A, vol. 1012, no. 2, pp. 161-168, 2003.

[41] J. D. Rabinowitz and E. Kimball, "Acidic acetonitrile for cellular metabolome extraction from Escherichia coli," Analytical Chemistry, vol. 79, no. 16, pp. 6167-6173, 2007.

[42] L. Brugnara, M. Vinaixa, S. Murillo et al., "Metabolomics approach for analyzing the effects of exercise in subjects with type 1 diabetes mellitus," PLoS ONE, vol. 7, no. 7, Article ID e40600, 2012.

Omar Al Kadhi, (1,2) Antonietta Melchini, (1) Richard Mithen, (1) and Shikha Saha (1)

(1) Food and Health Programme, Quadram Institute Bioscience, Norwich NR4 7UA, UK

(2) Department of Urology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK

Correspondence should be addressed to Shikha Saha;

Received 27 February 2017; Accepted 5 June 2017; Published 18 September 2017

Academic Editor: Nuria Fontanals

Caption: Figure 1: Chemical structure of TCA cycle intermediates.

Caption: Figure 2: LC-MS/MS chromatograms of TCA cycle intermediates in human plasma. (a) Citric (CA) and isocitric (ICA) acids; (b) malic acid (MA); (c) succinic acid (SA); (d) fumaric acid (FA); (e) glutamic acid (GA); (f) lactic acid (LA).

Caption: Figure 3: LC-MS/MS chromatograms of TCA cycle intermediates in human urine. (a) Citric (CA) and isocitric (ICA) acids; (b) malic acid (MA); (c) succinic acid (SA); (d) glutamic acid (GA); (e) lactic acid (LA).

Caption: Figure 4: Identification and quantification of citric acid (CA) in human prostate tissue. (a) LC-MS/MS chromatogram of citric acid (CA) in benign tissue. (b) LC-MS/MS chromatogram of citric acid (CA) in cancer tissue. (c) Average concentrations (nM) of citric acid in benign and cancer tissue. Frozen tissue samples were ground to powder before subsequent extraction. Citric acid (nM) was quantified from benign (n = 5) and cancer (n = 5) prostate tissue samples using LC-MS/MS. The results are corrected for tissue weight. Mean values are shown as "+." Statistical analysis was performed with Student's i-test (p = 0.0579).

Caption: Figure 5: LC-MS/MS chromatograms of TCA cycle intermediates extracted from human cultured PC3 cells. (a) Citric (CA) and isocitric (ICA) acids; (b) succinic acid (SA); (c) fumaric acid (FA); (d) malic acid (MA); (e) glutamic acid (GA); (f) lactic acid (LA).
Table 1: LC-MS/MS parameters of each analyte.

                            Retention    Precursor    Product
                              time          ion         ion
Analyte                       (min)        (m/z)       (m/z)

D4-citric acid                 1.13         195         114
D4-citric acid                 1.13         195         177
Isocitric acid                 0.85         191         155
Citric acid                    1.13         191         111
Citric acid                    1.13         191          87
Glutamic acid                  0.6          148         130
Glutamic acid                  0.6          148          84
Malic acid                     0.7          133         115
Malic acid                     0.7          133          71
Succinic acid                  1.6          117          99
Succinic acid                  1.6          117          73
Fumaric acid                   1.3          115          71
Fumaric acid                   1.3          115          41
Lactic acid                    1.05          89          43
[alpha]-Ketoglutaric acid      1.03         145         101
[alpha]-Ketoglutaric acid      1.03         145          57
Oxaloacetic acid               0.58         131          87
Oxaloacetic acid               0.58         131          41

                            Collision    accelerator
Analyte                       energy       voltage      Polarity

D4-citric acid                  12            4         Negative
D4-citric acid                  10            4         Negative
Isocitric acid                  10            5         Negative
Citric acid                     10            5         Negative
Citric acid                     18            5         Negative
Glutamic acid                   8             4         Positive
Glutamic acid                   12            4         Positive
Malic acid                      10            5         Negative
Malic acid                      14            5         Negative
Succinic acid                   10            5         Negative
Succinic acid                   10            5         Negative
Fumaric acid                    10            5         Negative
Fumaric acid                    18            5         Negative
Lactic acid                     10            4         Negative
[alpha]-Ketoglutaric acid       10            5         Negative
[alpha]-Ketoglutaric acid       10            5         Negative
Oxaloacetic acid                10            5         Negative
Oxaloacetic acid                54            5         Negative

Table 2: Validation data for each analyte in human plasma.

                 Linearity                 Precision
                   range                  intraday (%)
Analyte          ([micro]M)   [R.sup.2]     (n = 10)

Citric acid        0-520       0.9998          4.9
Isocitric acid     0-520       0.9997          4.6
Malic acid         0-372       0.9999          8.9
Lactic acid        0-1100      0.9987         4.44
Succinic acid      0-840       0.9998          8.1
Fumaric acid       0-430       0.9998          8.8
Glutamic acid      0-340       0.9998          7.4

                 interday (%)
Analyte             (n = 5)      LOD *   LOQ *

Citric acid           6.3        0.06    0.18
Isocitric acid       10.5        0.06    0.18
Malic acid           13.5        0.06    0.18
Lactic acid           9.9          1       3
Succinic acid        18.9        0.06    0.18
Fumaric acid         12.2          1       3
Glutamic acid        12.6        0.05    0.15

* Values in [micro]M for 1: 10 sample dilution.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Kadhi, Omar Al; Melchini, Antonietta; Mithen, Richard; Saha, Shikha
Publication:Journal of Analytical Methods in Chemistry
Article Type:Report
Date:Jan 1, 2017
Previous Article:Supercritical Fluid Chromatography of Drugs: Parallel Factor Analysis for Column Testing in a Wide Range of Operational Conditions.
Next Article:Stable Isotope Ratio and Elemental Profile Combined with Support Vector Machine for Provenance Discrimination of Oolong Tea (Wuyi-Rock Tea).

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |